Q-omics provides the consensus-scored ETS2 profile across patient tissues and cancer cell-line models. ETS2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ETS2 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, ETS2 RNA expression shows 18,983 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KICH, and THYM as cancer lineages where ETS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETS2 survival associations across molecular data types. ETS2 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETS2 RNA expression–survival associations across cancer types. High ETS2 expression shows unfavorable associations in UVM, KIRP and MESO, but favorable associations in LIHC, UCEC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UVM as the clearest survival context for ETS2 RNA expression.
This table summarizes ETS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ETS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETS2 shows lower tumor expression in KICH, KIRP, LUAD, BLCA, LIHC and BRCA. The KICH box plot shows higher ETS2 RNA expression in normal versus tumor tissue (log2 FC = −2.315, t-test p < 0.001).
This table shows molecular features associated with ETS2 in patient tissues and cancer cell lines. In patient samples, ETS2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ETS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
